Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Massachusetts Weekly.
Press releases published on April 22, 2025

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala
Biotechnology and pharmaceutical industry veteran, Abizer Gaslightwala, shares his vision for Akari moving forward Access the video here BOSTON and LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company …

Cangrade Launches Generative AI-Powered Soft and Hard Skills Assessments, Expanding Accessibility to HR Teams
WATERTOWN, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Cangrade today announced the launch of generative AI-powered soft and hard skills assessments. Created instantly from a simple job description, HR teams can now access quick, customized, high-quality and …

Harbinger Health Strengthens Leadership Team and Board of Directors
Executive appointments include Matt Turner as President and Hutan Ashrafian, M.D., Ph.D., M.B.A., as Chief Medical Officer Ajit Singh, M.S., Ph.D., joins Board of Directors Additions of industry leaders in clinical development, cancer research and market …

Paytronix Celebrates 10th Client Conference, PX|NXT with Leading Brands in Hospitality Guest Experience
NEWTON, Mass. and NASHVILLE, Tenn., April 22, 2025 (GLOBE NEWSWIRE) -- Paytronix, an Access Group company and leader in guest engagement for restaurants and convenience stores, will host their premier guest engagement event next week, as Paytronix clients …

HYCU® Spotlighted Across 101 G2 Reports with Leadership Status in Six Categories
Boston, Massachusetts, April 22, 2025 (GLOBE NEWSWIRE) -- HYCU, Inc., a leader for modern data protection for on-prem, cloud services, and SaaS, and one of the fastest growing companies in the industry, announced HYCU was acknowledged as a leader by G2, …

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025
CAMBRIDGE, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that new data will be presented at the American …

Liberty Defense has Appointed the Honorable James M. Byrne, Former Deputy Secretary of Veterans Affairs & Current Vice President, Ethics & Business Conduct, for the Lockheed Martin Corporation, to its Newly Formed Strategic Advisory Board
WILMINGTON, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (TSXV: SCAN, OTCQB: LDDFF, FSE:E30) a leading technology provider of AI-based next generation security detection solutions for concealed …

FluidForm Bio™ Strengthens IP Portfolio with Newly Issued Patent on Key Aspects of its Proprietary FRESH™ Platform
WALTHAM, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,215,202 B2, …

Byrna Technologies Announces the Debut of the Byrna CL, the World’s Most Concealable Less-Lethal Launcher
ANDOVER, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Byrna Technologies Inc. (“Byrna” or the “Company”) (Nasdaq: BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security …

Auto Shanghai 2025: Cerence AI Partners with Industry Leaders to Showcase xUI, its Hybrid, Agentic AI Assistant Platform
SHANGHAI and BURLINGTON, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global leader pioneering conversational AI-powered user experiences, will demo Cerence xUI™, its agentic AI assistant platform that works …

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025 Two parallel Phase 2b trials in AD and asthma …

ThermoFab Expands Capabilities with Acquisition of RIM Molding Assets
SHIRLEY, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- ThermoFab, a trusted leader in thermoforming and injection molding heavy gauge plastic enclosures and single use components for medical device and other critical highly regulated industries, is pleased to …

Rapport Therapeutics to Participate in Upcoming Investor Conferences
BOSTON and SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for …